What happens when HIV is treated extremely early after HIV acquisition? A man on PrEP was diagnosed with an HIV RNA of 220, 4th generation Ag/Ab negative, around 10 days after acquiring HIV. He was treated for 34 months with combination ART, which led to numerous negative reservoir assays, then stopped treatment -- only to experience virologic rebound (same as original infecting virus) 225 days later. In summary, reservoir and viral diversity were reduced -- but virus not eradicated.
Weekly MK-8591 effective in animal model of PrEP. The drug, a "nucleoside reverse transcriptase translocation inhibitor" with a mechanism of action somewhat different from current NRTIs, is highly potent with a long half life. Study used rhesus macaques and SIV; none became infected after SIV challenge that infected untreated controls.
Doravirine/TDF/3TC non-inferior to EFV/TDF/FTC. 84% vs 81% < 50 at week 48. DOR with significantly fewer CNS side effects, better lipids. 1.6% of DOR vs 3.3% of EFV subjects with resistance. Results of this and prior phase 3 DOR study suggest this NNRTI has the best efficacy, safety, and tolerability profile in this drug class.
3TC was non-inferior to TDF/3TC when given with fixed-dose DRV/r. With the caveat that this is an interim analysis of a fully powered study, and used a 400 copy/mL threshold, the results are encouraging -- and DRV/r + 3TC is a much more attractive regimen than the LPV/r + 3TC regimen used in GARDEL. Note the use of a non-FDA approved DRV/r coformulation (study done in Argentina). In the USA, this would presumably be DRV/c, can we extrapolate?
With 2 NRTIs, DTG superior to LPV/r as 2nd-line therapy after failure of a 2-NRTI/NNRTI-based regimen. The results so favored the DTG strategy that the study's Independent Data Monitoring Committee stopped the LPV/r arm (all subjects are now receiving DTG). Findings should have a huge impact on clinical practice -- will DTG (not boosted PI) based regimens now be the standard of care for second-line therapy? Can we extrapolate to those currently virologically suppressed on boosted PIs + NRTIs due to NRTI resistance?
What a weird conference center. Numerous escalators, winding hallways, and a disorienting layout made getting around tricky. At least the session halls for the slide sessions were very comfortable (though some over-crowded).
Why can't we have a subway system like that? The Paris Metro seems to get better all the time -- fast, clean, reliable, inexpensive. I'm sure it's not perfect, but is there a better urban rapid transit system in a large city anywhere else?
This article was provided by Journal Watch. It is a part of the publication The 9th Conference on Retroviruses and Opportunistic Infections. Journal Watch is a publication of the Massachusetts Medical Society.
(Please note: Your name and comment will be public, and may even show up in Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.)
HIV Care Today is a multi-author blog featuring people on the frontlines of HIV treatment, prevention and patient/client care. This blog serves as a platform for these health care professionals to discuss the everyday challenges of their jobs, recent developments in their fields and issues relevant to the evolution of HIV/AIDS care.
TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.